Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elezanumab in relapsing forms of multiple sclerosis
NCT02601885Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of elezanumab in multiple sclerosis (MS) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Number and percentage of participants reporting adverse events, Concentration of anti-drug antibody (ADA) titers of ABT-555 and 3 more. Started Oct 2016; status: completed.
02
Drugs
elezanumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02601885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02601885.